Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial - Poll - MDSpire

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

  • By

  • Hao-Rui Shen

  • Jia-Zhu Wu

  • Hua Yin

  • Kai-Xin Du

  • Luthuli Sibusiso

  • Yi-Fan Wu

  • Wei Hua

  • Yue Li

  • Yi-Lin Kong

  • Xin-Yu Zhang

  • Rui Gao

  • Jian-Yong Li

  • Li Wang

  • Jin-Hua Liang

  • Wei Xu

  • February 11, 2026

  • 0 min

Share

Original Source(s)

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

  • by Hao-Rui Shen, Jia-Zhu Wu, Hua Yin, Kai-Xin Du, Luthuli Sibusiso, Yi-Fan Wu, Wei Hua, Yue Li, Yi-Lin Kong, Xin-Yu Zhang, Rui Gao, Jian-Yong Li, Li Wang, Jin-Hua Liang, Wei Xu

  • February 11, 2026

Related Content

Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model

Susceptibility- and T2*-weighted MRI features of CNS large B-cell lymphoma in a large single-center cohort: prevalence, patterns, and clinical associations

Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma